Last $15.79 USD
Change Today +0.61 / 4.02%
Volume 758.4K
As of 8:10 PM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Henry E. Blair

Co-Founder, Chairman of The Board and Member of Strategy & Science Committee, Dyax Corp.
AgeTotal Calculated CompensationThis person is connected to 13 board members in 3 different organizations across 7 different industries.

See Board Relationships
70$271,000

Background*

Mr. Henry E. Blair was a Co-founder of Genzyme Corporation. Mr. Blair is a Co-Founder of Dyax Corporation and served as its Chief Executive Officer from 1997 to January 01, 2009 and the President from August 1995 to January 01, 2009. He co-founded Biocode, Inc., and GelTex Pharmaceuticals, Inc. Mr. Blair has been the Chairman of Dyax Corporation since August 1995 and as its Director since 1989. Mr. Blair served as a Director of Esperion Therapeutics, Inc.

Corporate Headquarters*

55 Network Drive
Burlington, Massachusetts 01803

United States

Phone: 617-225-2500
Fax: 617-225-2501

Board Members Memberships*

Former Director
Director
1981-N/A
Former Director
1981-2007
Co- Founder
1981-N/A
Former Director
1981-N/A
Co-Founder
1989-Present
Co-Founder, Chairman of The Board and Member of Strategy & Science Committee
1995-N/A
Former Director
2001-N/A
Former Director

Education*

There is no Education data available.

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

Total Annual Cash Compensation$98,500
Total Calculated Compensation$271,000
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DYAX:US $15.79 USD +0.61

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Jon P. Stonehouse Chief Executive Officer, President and Executive Director
BioCryst Pharmaceuticals, Inc.
$475.7K
Sijmen de Vries M.D., MBAChief Executive Officer and Member of Management Board
Pharming Group NV
€546.0K
John W. Varian Chief Executive Officer, President and Director
XOMA Corporation
$489.3K
Simon E. Moroney Ph.D.Chairman of Management Board and Chief Executive Officer
Morphosys AG
€772.6K
Jan G. J. van de Winkel Ph.D.Co-Founder, Chief Executive Officer and President
Genmab A/S
kr10.7M
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DYAX CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.